Ladenburg Thalmann Reiterates Buy, $119 PT on Kiora Pharmaceuticals (KPRX)
Tweet Send to a Friend
Ladenburg Thalmann analyst Matt Kaplan reiterated a Buy rating and $119.00 price target on Kiora Pharmaceuticals (NASDAQ: KPRX) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
